生存期-话题@MedSci

#生存期#

350篇内容 | 3601人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378089, encodeId=39ad13e808927, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Psychosom Med：抑郁会降低癌症患者生存期, objectType=article, longId=60979, objectId=5b3f609e946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3f609e946, replyNumber=0, likeNumber=66, createdTime=2015-12-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3f609e946, moduleTitle=Psychosom Med：抑郁会降低癌症患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3f609e946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378088, encodeId=32a413e80886d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期, objectType=article, longId=60882, objectId=3e5560882c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5560882c0, replyNumber=0, likeNumber=60, createdTime=2015-12-22, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5560882c0, moduleTitle=Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5560882c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378087, encodeId=042813e8087af, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ASH 2015：免疫调节单抗elotuzumab持续改善多发性骨髓瘤无进展生存期, objectType=article, longId=60415, objectId=514f6041501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=514f6041501, replyNumber=0, likeNumber=64, createdTime=2015-12-10, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=514f6041501, moduleTitle=ASH 2015：免疫调节单抗elotuzumab持续改善多发性骨髓瘤无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=514f6041501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378086, encodeId=012f13e808676, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ASA 2015：治疗便秘药物Relistor可延长癌症患者总生存期, objectType=article, longId=58057, objectId=317e5805e9d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317e5805e9d, replyNumber=0, likeNumber=87, createdTime=2015-10-31, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317e5805e9d, moduleTitle=ASA 2015：治疗便秘药物Relistor可延长癌症患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=317e5805e9d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378085, encodeId=580513e808538, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=BMJ：别犹豫！紧急转诊也能延长肿瘤患者生存期, objectType=article, longId=57365, objectId=771e5e3652b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=771e5e3652b, replyNumber=0, likeNumber=75, createdTime=2015-10-18, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=771e5e3652b, moduleTitle=BMJ：别犹豫！紧急转诊也能延长肿瘤患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=771e5e3652b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378084, encodeId=f8d413e808477, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=难治性肺鳞状细胞癌患者接受阿法替尼治疗后的生存期优于特罗凯, objectType=article, longId=56751, objectId=154056e51aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=154056e51aa, replyNumber=0, likeNumber=95, createdTime=2015-10-01, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=154056e51aa, moduleTitle=难治性肺鳞状细胞癌患者接受阿法替尼治疗后的生存期优于特罗凯, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=154056e51aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378083, encodeId=138913e8083e5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncol：疲劳评估对骨髓增生异常综合征等患者的总生存期有预后价值, objectType=article, longId=56519, objectId=63bc5651986, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63bc5651986, replyNumber=0, likeNumber=106, createdTime=2015-09-25, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63bc5651986, moduleTitle=Lancet Oncol：疲劳评估对骨髓增生异常综合征等患者的总生存期有预后价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63bc5651986)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378082, encodeId=55ee13e808215, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAGS：化疗并不能延长老年乳腺癌患者生存期, objectType=article, longId=54938, objectId=4c00549381e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c00549381e, replyNumber=0, likeNumber=79, createdTime=2015-08-18, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c00549381e, moduleTitle=JAGS：化疗并不能延长老年乳腺癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c00549381e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378081, encodeId=eeba13e8081ca, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Cancer Cell：生物标志物CSN6预示结直肠癌生存期, objectType=article, longId=54757, objectId=9e5054e57e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e5054e57e4, replyNumber=0, likeNumber=90, createdTime=2015-08-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e5054e57e4, moduleTitle=Cancer Cell：生物标志物CSN6预示结直肠癌生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e5054e57e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378080, encodeId=749513e808018, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncol：新辅助化放疗加手术可提高食管和交界癌患者的总生存期, objectType=article, longId=54560, objectId=d5ed54560fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5ed54560fc, replyNumber=0, likeNumber=71, createdTime=2015-08-08, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5ed54560fc, moduleTitle=Lancet Oncol：新辅助化放疗加手术可提高食管和交界癌患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5ed54560fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378079, encodeId=039b13e807950, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=NEJM：多西他赛加ADT治疗显著延长转移性前列腺癌患者的总生存期, objectType=article, longId=54489, objectId=7cf754489be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cf754489be, replyNumber=0, likeNumber=95, createdTime=2015-08-07, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cf754489be, moduleTitle=NEJM：多西他赛加ADT治疗显著延长转移性前列腺癌患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cf754489be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378078, encodeId=f7db13e807851, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究), objectType=article, longId=54327, objectId=0ab65432efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ab65432efa, replyNumber=0, likeNumber=31, createdTime=2015-08-03, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ab65432efa, moduleTitle=Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ab65432efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378077, encodeId=96f813e8077eb, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期, objectType=article, longId=52073, objectId=0df1520e32c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0df1520e32c, replyNumber=0, likeNumber=28, createdTime=2015-06-17, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0df1520e32c, moduleTitle=诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0df1520e32c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378076, encodeId=8d4d13e807694, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Ann Oncol：早期结肠癌生存期与普通人群（MGP）生存期比较, objectType=article, longId=51616, objectId=e08451616dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e08451616dd, replyNumber=0, likeNumber=74, createdTime=2015-06-05, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e08451616dd, moduleTitle=Ann Oncol：早期结肠癌生存期与普通人群（MGP）生存期比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e08451616dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378075, encodeId=3f7513e8075ff, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ASCO 2015：前瞻性TKI 直接比较的晚期肺鳞癌研究，阿法替尼总生存期更优（LUX-Lung 8）, objectType=article, longId=51535, objectId=af6f5153537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af6f5153537, replyNumber=0, likeNumber=97, createdTime=2015-06-04, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af6f5153537, moduleTitle=ASCO 2015：前瞻性TKI 直接比较的晚期肺鳞癌研究，阿法替尼总生存期更优（LUX-Lung 8）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af6f5153537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378074, encodeId=da5c13e8074a4, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Nature：突变p53基因可能改善肿瘤患者的生存期, objectType=article, longId=51337, objectId=dfae5133e1d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfae5133e1d, replyNumber=0, likeNumber=72, createdTime=2015-05-30, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfae5133e1d, moduleTitle=Nature：突变p53基因可能改善肿瘤患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfae5133e1d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378073, encodeId=1d3013e8073ff, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncol：Ombrabulin+cisplatin显著提高软组织肉瘤的无进展生存期, objectType=article, longId=50458, objectId=f1ef504589c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1ef504589c, replyNumber=0, likeNumber=72, createdTime=2015-05-10, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1ef504589c, moduleTitle=Lancet Oncol：Ombrabulin+cisplatin显著提高软组织肉瘤的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1ef504589c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378072, encodeId=c88b13e8072cf, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JCO：舒尼替尼维持治疗可改善小细胞肺癌无进展生存期PFS（II期研究）, objectType=article, longId=50196, objectId=b7285019648, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7285019648, replyNumber=0, likeNumber=74, createdTime=2015-05-06, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7285019648, moduleTitle=JCO：舒尼替尼维持治疗可改善小细胞肺癌无进展生存期PFS（II期研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7285019648)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378071, encodeId=07a813e807105, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期, objectType=article, longId=50059, objectId=70ba50059c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ba50059c4, replyNumber=0, likeNumber=105, createdTime=2015-05-01, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ba50059c4, moduleTitle=BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ba50059c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378070, encodeId=9b7613e8070b5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncology：Ipilimumab延长晚期黑色素瘤术后患者生存期, objectType=article, longId=49652, objectId=a76c496528e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a76c496528e, replyNumber=0, likeNumber=86, createdTime=2015-04-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a76c496528e, moduleTitle=Lancet Oncology：Ipilimumab延长晚期黑色素瘤术后患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a76c496528e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存期

2020-05-29

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Psychosom Med：抑郁会降低癌症患者生存期

2015-12-23

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet：Pembrolizumab能够显著延长PD-L1阳性晚期非小细胞肺癌患者的生存期

2015-12-22

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ASH 2015：免疫调节单抗elotuzumab持续改善多发性骨髓瘤无进展生存期

2015-12-10

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ASA 2015：治疗便秘药物Relistor可延长癌症患者总生存期

2015-10-31

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

BMJ：别犹豫！紧急转诊也能延长肿瘤患者生存期

2015-10-18

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

难治性肺鳞状细胞癌患者接受阿法替尼治疗后的生存期优于特罗凯

2015-10-01

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncol：疲劳评估对骨髓增生异常综合征等患者的总生存期有预后价值

2015-09-25

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JAGS：化疗并不能延长老年乳腺癌患者生存期

2015-08-18

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Cancer Cell：生物标志物CSN6预示结直肠癌生存期

2015-08-13

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncol：新辅助化放疗加手术可提高食管和交界癌患者的总生存期

2015-08-08

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

NEJM：多西他赛加ADT治疗显著延长转移性前列腺癌患者的总生存期

2015-08-07

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究)

2015-08-03

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期

2015-06-17

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Ann Oncol：早期结肠癌生存期与普通人群（MGP）生存期比较

2015-06-05

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ASCO 2015：前瞻性TKI 直接比较的晚期肺鳞癌研究，阿法替尼总生存期更优（LUX-Lung 8）

2015-06-04

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Nature：突变p53基因可能改善肿瘤患者的生存期

2015-05-30

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncol：Ombrabulin+cisplatin显著提高软组织肉瘤的无进展生存期

2015-05-10

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JCO：舒尼替尼维持治疗可改善小细胞肺癌无进展生存期PFS（II期研究）

2015-05-06

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

BMC Cancer：FGFR1和FRS2α的表达增加会降低RCC患者的无进展生存期

2015-05-01

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncology：Ipilimumab延长晚期黑色素瘤术后患者生存期

2015-04-23

科室
- - 订阅+
  - 更多科室
工具
服务